Bioscrip Inc (NASDAQ:BIOS): Positive Stock Sentiment

April 17, 2018 - By Linda Rogers

BioScrip, Inc. (NASDAQ:BIOS) Logo

Sentiment for Bioscrip Inc (NASDAQ:BIOS)

Bioscrip Inc (NASDAQ:BIOS) institutional sentiment increased to 1.18 in Q4 2017. Its up 0.13, from 1.05 in 2017Q3. The ratio improved, as 47 investment managers opened new and increased holdings, while 40 cut down and sold their stock positions in Bioscrip Inc. The investment managers in our partner’s database now possess: 104.07 million shares, down from 104.38 million shares in 2017Q3. Also, the number of investment managers holding Bioscrip Inc in their top 10 holdings was flat from 3 to 3 for the same number . Sold All: 12 Reduced: 28 Increased: 28 New Position: 19.

BioScrip, Inc. provides home infusion services in the United States. The company has market cap of $334.57 million. The firm engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. It currently has negative earnings. It is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

The stock increased 1.55% or $0.04 during the last trading session, reaching $2.62. About 31,248 shares traded. BioScrip, Inc. (NASDAQ:BIOS) has risen 42.70% since April 17, 2017 and is uptrending. It has outperformed by 31.15% the S&P500.

Analysts await BioScrip, Inc. (NASDAQ:BIOS) to report earnings on May, 3. They expect $-0.10 EPS, up 37.50 % or $0.06 from last year’s $-0.16 per share. After $-0.15 actual EPS reported by BioScrip, Inc. for the previous quarter, Wall Street now forecasts -33.33 % EPS growth.

Venor Capital Management Lp holds 26.5% of its portfolio in BioScrip, Inc. for 14.21 million shares. Coliseum Capital Management Llc owns 1.89 million shares or 3.5% of their US portfolio. Moreover, Wynnefield Capital Inc has 3.07% invested in the company for 3.06 million shares. The New York-based Gilder Gagnon Howe & Co Llc has invested 0.61% in the stock. Ares Management Llc, a California-based fund reported 6.36 million shares.#img1#

BioScrip, Inc. (NASDAQ:BIOS) Ratings Coverage

Ratings analysis reveals 100% of BioScrip Inc’s analysts are positive. Out of 3 Wall Street analysts rating BioScrip Inc, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3.0 while the high is $4.0. The stock’s average target of $3.58 is 36.64% above today’s ($2.62) share price. BIOS was included in 5 notes of analysts from November 2, 2017. SunTrust maintained BioScrip, Inc. (NASDAQ:BIOS) on Thursday, March 8 with “Buy” rating. The company was maintained on Wednesday, April 11 by Barrington. The rating was maintained by SunTrust with “Buy” on Thursday, November 2. The rating was maintained by SunTrust on Wednesday, December 20 with “Buy”. The stock has “Buy” rating by Jefferies on Thursday, November 2.

BioScrip, Inc. (NASDAQ:BIOS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.